IMUNON, Inc. Advances IMNN-001 for Ovarian Cancer With FDA Alignment on CMC Strategy Ahead of Phase 3 Trial

Quiver QuantitativeDec 19 08:14 ET

Imunon Announces Positive Outcome of Type C CMC Meeting With FDA on IMNN-001

TipRanksDec 19 08:10 ET

Express News | Imunon Inc: On Track to Initiate Phase 3 Pivotal Trial of Imnn-001 in Q1 of 2025

ReutersDec 19 08:05 ET

Express News | Imunon Inc - Aligns With FDA on Cmc Strategy for Phase 3 Trial

ReutersDec 19 08:05 ET

IMUNON Announces Positive CMC Meeting With FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer

ImunonDec 19 00:00 ET

Imunon Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow JonesDec 11 06:36 ET · Ratings